Quelicin (Succinylcholine Chloride Injection USP) 20mg/mL Multi-Dose Vial 10 mL x 25/Box **Refrigerated Item

Quelicin (Succinylcholine Chloride Injection) is a muscle relaxant used during surgeries or mechanical ventilation to facilitate intubation and ensure optimal conditions for surgical procedures. It acts quickly by depolarizing neuromuscular blockers to induce short-term paralysis. This medication is essential for skilled healthcare professionals in emergency settings for rapid sequence induction and tracheal intubation. It is vital for critical patient management, ensuring controlled muscle relaxation during medical interventions.

Quelicin (Succinylcholine Chloride Injection, USP) is a sterile, nonpyrogenic solution used as a short-acting neuromuscular blocker for intravenous administration. It is supplied in a concentration of 20 mg/mL in multi-dose vials. The pack contains 25 vials, each having a 10 mL capacity.

Details and Features:

Concentration: 20 mg/mL of succinylcholine chloride.
Formulation: Multi-dose vials, ensuring versatility in dosing requirements.
Packaging: 25 vials per box, suitable for bulk medical settings.
Administration Route: Intravenous use for rapid onset action.
Indication: Quelicin is primarily used to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Mechanism of Action:

Succinylcholine is a depolarizing neuromuscular blocker. It mimics the action of acetylcholine, binding to nicotinic receptors at the neuromuscular junction. This binding results in depolarization of the muscle endplate, leading initially to muscle fasciculations followed by paralysis. Its action is terminated by the rapid hydrolysis of succinylcholine by plasma cholinesterases, resulting in a brief duration of action.

Warnings:

• Malignant Hyperthermia: Succinylcholine may trigger this genetic disorder, characterized by a rapid increase in body temperature and severe muscle contractions. Early recognition and treatment with dantrolene is essential.
  
• Hyperkalemia Risk: Can cause significant potassium release, resulting in potentially life-threatening hyperkalemia, especially in patients with burns, neurological disorders, or muscle trauma.
  
• Cardiac Arrest: Rare cases have been reported in children, typically associated with undiagnosed neuromuscular disorders.
  
• Prolonged Paralysis: May occur in individuals with atypical plasma cholinesterase or other conditions affecting metabolism or excretion.
  
• Anaphylaxis: As with other neuromuscular blockers, potential for severe allergic reactions exists.

Side Effects:

• Muscle Fasciculations: Visible muscle twitches prior to paralysis.
  
• Bradycardia or Tachycardia: Changes in heart rate can occur post-administration.
  
• Increased Intraocular Pressure: May transiently increase eye pressure.
  
• Myoglobinemia/Myoglobinuria: Rhabdomyolysis can occur.
  
• Prolonged Apnea: Particularly in cases of pseudocholinesterase deficiency.

Clinical Consideration:

• Monitoring: Use with appropriate monitoring of neuromuscular function, especially in settings lacking emergency equipment.
  
• Patient History: Thorough assessment of the patient's medical history and potential risk factors for complications is necessary before administration.
  
• Resuscitation Equipment: Immediate availability of resuscitative drugs and equipment is mandatory when using this medication.

Always consult the prescribing information and a healthcare professional for comprehensive details and specific clinical use cases.